Koda Et Al Diabetes 1995

1. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005; 1(1):22-31.

2. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second ├č-cell hormone. Diabetes Technol Ther 2002; 4:175-89.

3. Koda JE, Fineman M, Rink TJ, et al. Amylin concentrations and glucose control. Lancet 1992; 339: 1179-80.

4. Koda JE, Fineman MS, Kolterman OG, et al. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls [abstract 876]. Diabetes 1995; 44(Suppl. 1):238A.

5. Fineman MS, Giotta MP, Thompson RG, et al. Amylin response following Sustacal® ingestion is diminished in type II diabetic patients treated with insulin [abstract 556]. Diabetologia 1996; 39 (Suppl. 1):A149.

6. Weyer C, Maggs DG, Young AA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7(14):1353-73.

7. Young A, Moore C, Herich J, et al. Neuroendocrine actions of amylin. In: Poyner D, Marshall I, Brain SD, eds. The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin. Georgetown, TX: Landes Bioscience, 2000:91-102.

8. Beaumont K, Kenney MA, Young AA, et al. High affinity amylin binding sites in rat brain. Mol Pharmacol 1993; 44(3):493-7.

9. Gedulin B, Jodka C, Green D, et al. Amylin inhibition of arginine-induced glucagon secretion: comparison with glucagon-like-peptide-1 (7-36)-amide (GLP-1) [abstract 584]. Diabetologia 1996; 39 (Suppl. 1):A154.

10. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 1997; 46(1):67-70.

11. Gedulin B, Jodka C, Percy A, et al. Neutralizing antibody and the antagonist AC187 may inhibit glucagon secretion in rats. Diabetes 1997; 40(Suppl. 1):238A.

12. Silvestre RA, Rodriguez-Gallardo J, Jodka C, et al. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab 2001; 280(3):E443-9.

13. Young AA, Gedulin B, Vine W, et al. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995; 38(6):642-8.

14. Young AA, Gedulin BR, Rink TJ. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 1996; 45(1):1-3.

15. Rushing PA, Hagan MM, Seeley RJ, et al. Amylin: a novel action in the brain to reduce body weight. Endocrinology 2000; 141(2):850-3.

16. Rushing PA. Central amylin signaling and the regulation of energy homeostasis. Curr Pharm Des 2003; 9(10):819-25.

17. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999; 25(3):389-97.

18. Janes S, Gaeta L, Beaumont K, et al. The selection of pramlintide for clinical evaluation. Diabetes 1996; 45(Suppl. 2):235A.

19. Young AA, Vine W, Gedulin BR, et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res 1996; 37(4):231-48.

20. [SYMLIN] Amylin Pharmaceuticals, Inc. 2005. SYMLIN prescribing information [online]. Accessed on 18 July 2006. URL: http://symlin.com/pdf/SYMLIN-pi-combined.pdf.

21. Fineman M, Weyer C, Maggs DG, et al. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002; 34:504-8.

22. Nyholm B, Moller N, Gravholt CH, et al. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81(3):1083-9.

23. Nowak TV, Johnson CP, Kalbfleisch JH, et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 1995; 37:23-9.

24. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109:755-65.

25. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996; 19:468-71.

26. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24:371-81.

27. Kong MF, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 1997; 40:82-8.

28. Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998; 41(5):577-83.

29. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48(5):838-48.

30. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a one-year randomized controlled trial. Diabetes Care 2003; 26(3):784-90.

31. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4(1):51-61.

32. Thompson RG, Gottlieb A, Organ K, et al. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin and c-peptide concentrations in patients with type II diabetes. Diabetes Technol Ther 2007; 9:191-199.

33. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 2004; 20:55-60.

34. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus. Treat Endocrinol 2003; 2:33-47.

35. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004; 12:661-8.

36. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006; 29(10): 2189-95.

37. Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions and weight. Diabetes Technol Ther 2007; 9:191-9.

38. Lush C, Strobel S, Zhang B, Frias J. Pramlintide, as an adjunct to long-acting insulin, led to improved A1C and body weight in patients with type 2 diabetes [abstract 521-P]. Diabetes 2006; 55:A124.

39. Frias J, Zhang B, Darsow T. Pramlintide as an adjunct to insulin glargine reduced A1C and body weight in patients with type 2 diabetes [abstract 472-P]. Diabetes 2006; 55:A112.

40. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19(3):257-67.

41. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17(3):189-212.

42. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000; 17(3):171-80.

43. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414 (6865):813-20.

44. Ceriello A, Lush C, Piconi L, et al. Pramlintide reduced markers of oxidative stress in the postprandial period in subjects with type 2 diabetes [abstract 447-P]. Diabetes 2006; 55:A106.

45. Weyer C, Fineman MS, Strobel S, et al. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm 2005; 62:816-22.

0 0

Post a comment